This funding opportunity supports preclinical and patient-based research examining the mechanisms through which incretin mimetics, including GLP-1, GIP-1, or dual agents, impact cancer risk. The goal is to understand how these agents influence cancer risk, with evidence suggesting differential effects on obesity-related cancers. The research should move beyond short-term outcomes like weight loss or diabetes to focus on cancer risk mechanisms.
Eligible applicants include a wide range of institutions such as private and public higher education institutions, nonprofits, for-profit organizations, tribal governments, small businesses, and various other specified entities including federal agencies and minority-serving institutions.
